glp-1 sleep apnea trial Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease Exploring GLP-1 prescriptions and comorbidites

Initially approved to treat diabetes, glucagon-like peptide-1 (GLP-1) drugs are being heralded to address obesity and, more recently, obstructive sleep apnea (OSA)

*FOR $49 VIRTUAL VISIT: For weight-loss related consultation at MinuteClinic only

Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis Diabetes

The US telehealth company confirmed today that it is launching an oral version of GLP-1 agonist semaglutide the active ingredient in Wegovy at a knockdown introductory price of $49 per month with a five-month plan